The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Fri., Nov. 28, 9:13 PM

Slide #21. Amicus Therapeutics Secondary Offering

Company: Amicus Therapeutics (NASDAQ:FOLD)
Date announced: 11/17/2014
Shares Offered: 13,850,000
Date of Pricing: 11/18/2014
Price Per Share: $6.50
Secondary Offering Details: Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced it has commenced a $75 million underwritten public offering of its common stock. J.P. Morgan Securities LLC is acting as sole book-running manager for the proposed offering. Cowen and Company, LLC and Leerink Partners are acting as lead managers and Janney Montgomery Scott is acting as co-manager for the offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the final size or terms of the offering. - updated 11/19 - Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced the pricing of an underwritten offering of 13,850,000 shares of its common stock at $6.50 per share. The gross proceeds from the offering to Amicus are expected to be $90.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Amicus. In addition, Amicus has granted the underwriters a 30-day option to purchase up to an additional 2,077,500 shares of its common stock. The offering is expected to close on November 24, 2014, subject to customary closing conditions.

Amicus Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of medicines for a range of diseases, with a focus on improved therapies for lysosomal storage disorders (LSDs). Co.'s development programs include enzyme replacement therapies (ERTs) for LSDs, including Fabry disease, Pompe disease and Mucopolysaccharoidosis Type I. Co. is also developing small molecules as monotherapy treatments for Fabry disease and Parkinson's disease. Co.'s main product candidate, migalastat HCl, is an investigational, small molecule pharmacological chaperone for the treatment of Fabry disease.
Open the FOLD Page at The Online Investor »

Company Name:  Amicus Therapeutics Inc
Website:  www.amicusrx.com
Sector:  Biotechnology
Number of ETFs Holding FOLD:  1
Total Market Value Held by ETFs:  $1.06M
Total Market Capitalization:  $645.00M
% of Market Cap. Held by ETFs:  0.17%
 

Open the FOLD Page at The Online Investor (in a new window) »

November 28, 2014    9:13 PM Eastern
Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
90th percentile
(ranked higher than approx. 90% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2014, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.